Trials / Completed
CompletedNCT04923269
A Study of LY3532226 in Healthy Participants
A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3532226 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 21 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3532226 in healthy participants. Blood tests will be performed to check how much LY3532226 gets into the bloodstream and how long it takes the body to eliminate it. This study will last approximately 8 weeks including screening period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3532226 | Administered SC. |
| DRUG | Placebo | Administered SC. |
Timeline
- Start date
- 2021-06-10
- Primary completion
- 2021-10-28
- Completion
- 2021-10-28
- First posted
- 2021-06-11
- Last updated
- 2021-12-17
Locations
1 site across 1 country: Singapore
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04923269. Inclusion in this directory is not an endorsement.